Persist AI Partners With CyanoCapture on GMP Robotic Oral Peptide Manufacturing

According to a recent LinkedIn post from Persist AI, the company is partnering with CyanoCapture to develop what is described as the world’s first GMP robotic manufacturing system for oral peptide delivery. The post highlights the combination of CyanoCapture’s engineered edible microbes for oral GLP‑1 delivery with Persist AI’s automation platform, which is being extended into GMP analytical work for rapid iteration and quality control at scale.

The post suggests this collaboration could position Persist AI at the intersection of AI, synthetic biology, and robotics in U.S. biomanufacturing. For investors, the partnership may signal a move toward scalable, automated production capabilities in the growing market for peptide-based therapeutics and GLP‑1 treatments, potentially enhancing Persist AI’s long-term competitive positioning and partnering optionality, though no financial terms or timelines are indicated.